Novus Therapeutics, Inc. (NVUS) Has Another Very Strong Trading Session

March 14, 2018 - By Winifred Garcia

The stock of Novus Therapeutics, Inc. (NASDAQ:NVUS) is a huge mover today! The stock increased 23.82% or $1.11 during the last trading session, reaching $5.77. About 216,008 shares traded or 331.99% up from the average. Novus Therapeutics, Inc. (NASDAQ:NVUS) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 9 months positive chart setup for the $40.88M company. It was reported on Mar, 14 by We have $6.23 PT which if reached, will make NASDAQ:NVUS worth $3.27M more.

More notable recent Novus Therapeutics, Inc. (NASDAQ:NVUS) news were published by: which released: “Novus Therapeutics Announces the Promotion of Dr. Catherine Turkel to President” on November 06, 2017, also with their article: “BRIEF-Andrew I. Mcdonald Reports 12.24 pct Passive Stake In Novus Therapeutics …” published on March 13, 2018, published: “Novus Therapeutics Inc.” on June 12, 2017. More interesting news about Novus Therapeutics, Inc. (NASDAQ:NVUS) were released by: and their article: “Otic Pharma Completes Merger with Tokai Pharmaceuticals” published on May 10, 2017 as well as‘s news article titled: “Novus Therapeutics Announces Change in Management” with publication date: July 10, 2017.

Novus Therapeutics, Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of ear, nose, and throat products. The company has market cap of $40.88 million. The Company’s lead product is a nasally-administered combination drug product intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD) conditions. It currently has negative earnings. The firm also has a foam drug delivery technology platform (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.